iHuman Inc. IH
Set alert
As of Oct 30, 10:14 AM ET
- YTD
- -43.81%
- 1 year
- -55.81%
- Open
- 1.18
- Prev close
- 1.18
- Mkt cap
- 60.32M
- Vol
- 477
- Avg vol
- 6.45K
- EPS
- 0.06
- P/E
- 19.67
- Div yield
- 0.00%
More statistics
- Low
- 1.18
- High
- 1.18
- Forward P/E
- 9.16
- Beta
- 0.47
- Short ratio
- 0.15
- Inst. own
- 0.62%
- Dividend
- 0.00
- Ex-div date
- Mar 26, 2024
- 50-d avg
- 1.74
- 200-d avg
- 1.77
- 1y target
- 0.00
6M chart
Signals (19)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 14, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 3, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 27, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 4, 2026 | 2 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| RSI: Oversold | Jun 9, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 4 months ago |
| SMA: Bearish | Jun 3, 2026 | 5 months ago |
| SMA: Bullish | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 29, 2026 | 5 months ago |
| MACD: Sell Signal | May 6, 2026 | 5 months ago |
Key statistics
- Market cap
- 91.12M
- Enterprise value
- -676.16M
- Trailing P/E
- 0.00
- Forward P/E
- 9.16
- PEG ratio
- 0.00
- Price / sales
- 0.09
- Price / book
- 0.10
- EPS (TTM)
- -0.16
- Beta
- 0.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 13.74%
- Revenue (TTM)
- 962.05M
- Revenue growth
- -10.70%
- Free cash flow
- 0
- Total cash
- 1.13B
- Total debt
- 2.87M
- Return on equity
- 14.79%
- Shares outstanding
- 23.57M
- Short % of float
- 0.02%
- 50-day average
- 1.74
- 200-day average
- 1.77
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 27, 2024 | Jun 1, 2024 | 0.00 | 0.06 | — | — |
| Jun 28, 2024 | Mar 1, 2024 | 0.00 | 0.06 | — | — |
| Feb 29, 2024 | Dec 1, 2023 | 0.00 | 0.09 | — | — |
| Dec 28, 2023 | Sep 1, 2023 | 0.00 | 0.14 | — | — |
| Sep 21, 2023 | Jun 1, 2023 | 0.00 | 0.11 | — | — |
| Jun 21, 2023 | Mar 1, 2023 | 0.00 | 0.15 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2020 | CMB International | init | — | Buy |
About iHuman Inc.
iHuman Inc. provides intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China. The company offers interactive and self-directed learning apps, including iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHuman Reading, iHumanpedia, iHuman Kids Workout, iHuman Coding, iHuman Fun Idioms, iHuman Little Artists, iHuman Writing, iHuman Fantastic Friends, and iHuman Readers; bekids Coding, bekids Coloring, bekids Reading, bekids Puzzle, bekids Academy, and Gogo Town; and Aha World, an open-ended interactive app that nurtures a desire for discovery. It provides intellectually stimulating materials, including books, interactive materials, and smart devices that develop children's abilities in speaking, critical thinking, independent reading, and creativity. iHuman Inc. was founded in 1996 and is based in Beijing, the People's Republic of China.
- Sector
- Consumer Defensive
- Industry
- Education & Training Services
- Country
- China
- Website
- ihuman.com
News
- Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
- Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
- Head-To-Head Contrast: IMAX (NYSE:IMAX) versus iHuman (NYSE:IH)
- iHuman Q2 Adj. EPS $(0.05) Down From $0.08 YoY, Sales $25.553M Down From $27.942M YoY
- iHuman Inc. Announces Second Quarter 2026 Unaudited Financial Results
- New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
- ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
- iHuman Q1 Adj. EPS $0.01 Down From $0.07 YoY, Sales $26.456M Down From $28.999M YoY
- iHuman Inc. Announces First Quarter 2026 Unaudited Financial Results
- Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
Your note
Sign in to keep a note on IH — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citadel Advisors Llc | 0.16% | 38,369 | 66.76K | Sep 29, 2024 |
| Morgan Stanley | 0.08% | 19,875 | 34.58K | Sep 29, 2024 |
| Rhumbline Advisers | 0.05% | 11,390 | 19.82K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.05% | 11,150 | 19.40K | Sep 29, 2024 |
| Credit Agricole S.A. | 0.04% | 10,000 | 17.40K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 4,526 | 7.88K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR Portfolio Emerging Markets ETF | 0.00% | 330 | 574 | Sep 29, 2024 |